Magnetic Resonance Therapy (MeRT) for PTSD in a Real-World Clinical Setting

following TMS.Response rates were comparable between non-THC users (56.6%) and active users (50.9%; p=0.559), as were remission rates for non-THC users (18.9%) and active users (17.0%; p=0.800).Independent samples t-tests demonstrated no difference in pre-to post-TMS PHQ-9 change between groups (p=0.347).Discussion: In this retrospective matched analysis, concurrent THC use during TMS was not associated with differential clinical outcomes compared with non-use.These findings suggest THC use during treatment doesn't meaningfully alter TMS effectiveness.Larger prospective studies are warranted to further elucidate the relationship between cannabis use patterns and TMS clinical outcomes for MDD.